FR2680687A1 - Compositions pharmaceutiques homeopathiques utilisees pour la fabrication de medicaments destines au traitement des maladies causees par des erreurs metaboliques et au traitement des maladies virales. - Google Patents
Compositions pharmaceutiques homeopathiques utilisees pour la fabrication de medicaments destines au traitement des maladies causees par des erreurs metaboliques et au traitement des maladies virales. Download PDFInfo
- Publication number
- FR2680687A1 FR2680687A1 FR9110899A FR9110899A FR2680687A1 FR 2680687 A1 FR2680687 A1 FR 2680687A1 FR 9110899 A FR9110899 A FR 9110899A FR 9110899 A FR9110899 A FR 9110899A FR 2680687 A1 FR2680687 A1 FR 2680687A1
- Authority
- FR
- France
- Prior art keywords
- viral
- treatment
- diseases
- metabolic
- intended
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 50
- 230000003612 virological effect Effects 0.000 title claims abstract description 34
- 230000001632 homeopathic effect Effects 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 9
- 230000002503 metabolic effect Effects 0.000 title claims abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 6
- 208000035475 disorder Diseases 0.000 title abstract 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- 239000012895 dilution Substances 0.000 claims abstract description 23
- 238000010790 dilution Methods 0.000 claims abstract description 23
- 239000002245 particle Substances 0.000 claims abstract description 18
- 239000000126 substance Substances 0.000 claims abstract description 18
- 230000008030 elimination Effects 0.000 claims abstract description 16
- 238000003379 elimination reaction Methods 0.000 claims abstract description 16
- 208000026350 Inborn Genetic disease Diseases 0.000 claims abstract description 8
- 208000016361 genetic disease Diseases 0.000 claims abstract description 8
- 230000006371 metabolic abnormality Effects 0.000 claims abstract description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 5
- 230000035987 intoxication Effects 0.000 claims abstract 3
- 231100000566 intoxication Toxicity 0.000 claims abstract 3
- 201000010099 disease Diseases 0.000 claims description 43
- 210000004027 cell Anatomy 0.000 claims description 35
- 230000003834 intracellular effect Effects 0.000 claims description 33
- 241000700605 Viruses Species 0.000 claims description 20
- 230000007812 deficiency Effects 0.000 claims description 19
- 239000008187 granular material Substances 0.000 claims description 17
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 13
- 239000011707 mineral Substances 0.000 claims description 13
- 230000002068 genetic effect Effects 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 9
- 208000030159 metabolic disease Diseases 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 230000007154 intracellular accumulation Effects 0.000 claims description 6
- 102000004310 Ion Channels Human genes 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 108010067390 Viral Proteins Proteins 0.000 claims description 5
- 230000002159 abnormal effect Effects 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 231100000331 toxic Toxicity 0.000 claims description 5
- 230000002588 toxic effect Effects 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- 210000000349 chromosome Anatomy 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 108020000999 Viral RNA Proteins 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 241000282324 Felis Species 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 206010019799 Hepatitis viral Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 201000001862 viral hepatitis Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 4
- 108020004414 DNA Proteins 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 abstract description 2
- 230000000607 poisoning effect Effects 0.000 abstract description 2
- 208000005374 Poisoning Diseases 0.000 abstract 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 230000032258 transport Effects 0.000 description 22
- 229910052742 iron Inorganic materials 0.000 description 14
- 235000010755 mineral Nutrition 0.000 description 12
- 235000002639 sodium chloride Nutrition 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 8
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 206010020850 Hyperthyroidism Diseases 0.000 description 7
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical group O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 206010039085 Rhinitis allergic Diseases 0.000 description 6
- 201000010105 allergic rhinitis Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- 201000003883 Cystic fibrosis Diseases 0.000 description 5
- 208000018565 Hemochromatosis Diseases 0.000 description 5
- 206010033799 Paralysis Diseases 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 5
- 229960001704 carbimazole Drugs 0.000 description 5
- CFOYWRHIYXMDOT-UHFFFAOYSA-N carbimazole Chemical compound CCOC(=O)N1C=CN(C)C1=S CFOYWRHIYXMDOT-UHFFFAOYSA-N 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 108090000862 Ion Channels Proteins 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- FAWGZAFXDJGWBB-UHFFFAOYSA-N antimony(3+) Chemical compound [Sb+3] FAWGZAFXDJGWBB-UHFFFAOYSA-N 0.000 description 4
- NVWBARWTDVQPJD-UHFFFAOYSA-N antimony(3+);trisulfide Chemical compound [S-2].[S-2].[S-2].[Sb+3].[Sb+3] NVWBARWTDVQPJD-UHFFFAOYSA-N 0.000 description 4
- 229910052785 arsenic Inorganic materials 0.000 description 4
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 4
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 3
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 3
- 206010036030 Polyarthritis Diseases 0.000 description 3
- 208000003217 Tetany Diseases 0.000 description 3
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 3
- 208000018839 Wilson disease Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 229960001955 benzylthiouracil Drugs 0.000 description 3
- PNXBXCRWXNESOV-UHFFFAOYSA-N benzylthiouracil Chemical compound N1C(=S)NC(=O)C=C1CC1=CC=CC=C1 PNXBXCRWXNESOV-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 208000030428 polyarticular arthritis Diseases 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 229940087854 solu-medrol Drugs 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 239000005495 thyroid hormone Substances 0.000 description 3
- 229940036555 thyroid hormone Drugs 0.000 description 3
- 229940078499 tricalcium phosphate Drugs 0.000 description 3
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 3
- 235000019731 tricalcium phosphate Nutrition 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010002953 Aphonia Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 206010018498 Goitre Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 235000019738 Limestone Nutrition 0.000 description 2
- 208000008167 Magnesium Deficiency Diseases 0.000 description 2
- 241000237502 Ostreidae Species 0.000 description 2
- 206010049226 Oxalosis Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000238370 Sepia Species 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- QSUCEFCBROHYLU-UHFFFAOYSA-N azane;mercury(2+);dinitrate Chemical compound N.N.[Hg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O QSUCEFCBROHYLU-UHFFFAOYSA-N 0.000 description 2
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000006028 limestone Substances 0.000 description 2
- 235000004764 magnesium deficiency Nutrition 0.000 description 2
- OKIWLDVQGKRUNR-UHFFFAOYSA-L magnesium;hydrogen phosphate;trihydrate Chemical compound O.O.O.[Mg+2].OP([O-])([O-])=O OKIWLDVQGKRUNR-UHFFFAOYSA-L 0.000 description 2
- 230000031852 maintenance of location in cell Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 235000020636 oyster Nutrition 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 208000007442 rickets Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- IHBMMJGTJFPEQY-UHFFFAOYSA-N sulfanylidene(sulfanylidenestibanylsulfanyl)stibane Chemical compound S=[Sb]S[Sb]=S IHBMMJGTJFPEQY-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001126923 Calcarea Species 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 235000001506 Ledum palustre Nutrition 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 208000005587 Refsum Disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 241000227142 Rhododendron tomentosum Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000030597 adult Refsum disease Diseases 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000003208 anti-thyroid effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- PUTWALAGSAIJLE-UHFFFAOYSA-L calcium 2-hydroxy-2-oxoacetate Chemical compound C(C(=O)[O-])(=O)[O-].C(C(=O)O)(=O)O.[Ca+2] PUTWALAGSAIJLE-UHFFFAOYSA-L 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- LQHWSGSWNOHVHO-UHFFFAOYSA-L calcium;oxalate;hydrate Chemical compound O.[Ca+2].[O-]C(=O)C([O-])=O LQHWSGSWNOHVHO-UHFFFAOYSA-L 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940098363 cuttle fish ink Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940099217 desferal Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000037119 hereditary cerebellar ataxia Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000000396 hypokalemic effect Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000019764 polyarticular juvenile idiopathic arthritis Diseases 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 208000007645 potassium deficiency Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9110899A FR2680687A1 (fr) | 1991-08-29 | 1991-08-29 | Compositions pharmaceutiques homeopathiques utilisees pour la fabrication de medicaments destines au traitement des maladies causees par des erreurs metaboliques et au traitement des maladies virales. |
| CA002142863A CA2142863A1 (fr) | 1991-08-29 | 1992-08-21 | Compositions homeopathiques pour le traitement des maladies virales et metaboliques |
| AU25105/92A AU2510592A (en) | 1991-08-29 | 1992-08-21 | Homeopathic compositions for the treatment of viral and metabolic diseases |
| DE69223811T DE69223811T2 (de) | 1991-08-29 | 1992-08-21 | Verwendung eines homöopathisches Erzeugnisses zur Herstellung eines Arzneimittels für die Behandlung von metabolischen Krankheiten |
| EP92918959A EP0655928B1 (fr) | 1991-08-29 | 1992-08-21 | Utilisation d'un produit homéopathique pour la préparation d'un médicament destiné au traitement de maladies métaboliques |
| PCT/FR1992/000813 WO1994004186A1 (fr) | 1991-08-29 | 1992-08-21 | Compositions homeopathiques pour le traitement des maladies virales et metaboliques |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9110899A FR2680687A1 (fr) | 1991-08-29 | 1991-08-29 | Compositions pharmaceutiques homeopathiques utilisees pour la fabrication de medicaments destines au traitement des maladies causees par des erreurs metaboliques et au traitement des maladies virales. |
| CA002142863A CA2142863A1 (fr) | 1991-08-29 | 1992-08-21 | Compositions homeopathiques pour le traitement des maladies virales et metaboliques |
| PCT/FR1992/000813 WO1994004186A1 (fr) | 1991-08-29 | 1992-08-21 | Compositions homeopathiques pour le traitement des maladies virales et metaboliques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2680687A1 true FR2680687A1 (fr) | 1993-03-05 |
| FR2680687B1 FR2680687B1 (enrdf_load_stackoverflow) | 1995-03-24 |
Family
ID=27169961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9110899A Granted FR2680687A1 (fr) | 1991-08-29 | 1991-08-29 | Compositions pharmaceutiques homeopathiques utilisees pour la fabrication de medicaments destines au traitement des maladies causees par des erreurs metaboliques et au traitement des maladies virales. |
Country Status (3)
| Country | Link |
|---|---|
| CA (1) | CA2142863A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2680687A1 (enrdf_load_stackoverflow) |
| WO (1) | WO1994004186A1 (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995015761A1 (fr) * | 1993-12-09 | 1995-06-15 | Labo'life | Solutions de type homeopathique contenant un acide nucleique |
| GB2296434A (en) * | 1994-12-30 | 1996-07-03 | Britannia Health Products Ltd | Compositions containing precious metals, particularly for the treatment of endometriosis |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6140305A (en) | 1996-04-04 | 2000-10-31 | Bio-Rad Laboratories, Inc. | Hereditary hemochromatosis gene products |
| US7026116B1 (en) | 1996-04-04 | 2006-04-11 | Bio-Rad Laboratories, Inc. | Polymorphisms in the region of the human hemochromatosis gene |
| US6849399B1 (en) | 1996-05-23 | 2005-02-01 | Bio-Rad Laboratories, Inc. | Methods and compositions for diagnosis and treatment of iron misregulation diseases |
| DE69841593D1 (de) | 1997-06-13 | 2010-05-12 | Bio Rad Laboratories | Verfahren und Zusammensetzungen für die Diagnose und die Behandlung von Krankheiten, die mit Eisenüberschuss oder Eisenmangel assoziiert sind |
| EP2568958A1 (en) * | 2010-05-14 | 2013-03-20 | Deseret Biologicals, Inc. | Formulations of diluted genetic material and methods for making same |
| US9603898B2 (en) | 2011-03-23 | 2017-03-28 | Deseret Biologicals, Inc. | Formulations of diluted amino acid segments and methods for making same |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0315552A1 (fr) * | 1987-10-08 | 1989-05-10 | Medibrevex Sa | Nouvelles formes galéniques d'oeufs de caille pour administration par voie per- et sublinguale dans le traitement des maladies allergiques et leur procédé de préparation |
-
1991
- 1991-08-29 FR FR9110899A patent/FR2680687A1/fr active Granted
-
1992
- 1992-08-21 CA CA002142863A patent/CA2142863A1/fr not_active Abandoned
- 1992-08-21 WO PCT/FR1992/000813 patent/WO1994004186A1/fr active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0315552A1 (fr) * | 1987-10-08 | 1989-05-10 | Medibrevex Sa | Nouvelles formes galéniques d'oeufs de caille pour administration par voie per- et sublinguale dans le traitement des maladies allergiques et leur procédé de préparation |
Non-Patent Citations (1)
| Title |
|---|
| G.NETIEN ET AL 'galenica 16 médicaments homéopathiques' 1986 , TECHNIQUE ET DOCUMENTATION , PARIS, FR * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995015761A1 (fr) * | 1993-12-09 | 1995-06-15 | Labo'life | Solutions de type homeopathique contenant un acide nucleique |
| FR2713487A1 (fr) * | 1993-12-09 | 1995-06-16 | Labo Life | Solutions de type homéopathique contenant un acide nucléique utilisables notamment dans la prévention ou le traitement de maladies infectieuses ou de maladies impliquant le dysfonctionnement d'un gène. |
| EP0670164A1 (fr) * | 1993-12-09 | 1995-09-06 | Labo'life | Solutions de type homéopathique contenant un acide nucléique |
| GB2296434A (en) * | 1994-12-30 | 1996-07-03 | Britannia Health Products Ltd | Compositions containing precious metals, particularly for the treatment of endometriosis |
| GB2296434B (en) * | 1994-12-30 | 1997-01-08 | Britannia Health Products Ltd | A homeopathic remedy comprising a precious metal salt |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2142863A1 (fr) | 1994-03-03 |
| FR2680687B1 (enrdf_load_stackoverflow) | 1995-03-24 |
| WO1994004186A1 (fr) | 1994-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chang et al. | Gabapentin in acute postoperative pain management | |
| Parfitt | Acetazolamide and sodium bicarbonate induced nephrocalcinosis and nephrolithiasis: relationship to citrate and calcium excretion | |
| Whelton et al. | Doxycycline pharmacokinetics in the absence of renal function | |
| SELENKOW et al. | The effectiveness of triiodothyronine or thyroxine administered orally in the treatment of myxedema | |
| JP2005538093A5 (enrdf_load_stackoverflow) | ||
| Vyth et al. | Survival in patients with amyotrophic lateral sclerosis, treated with an array of antioxidants | |
| Dwarakanath et al. | Sulphasalazine induced renal failure. | |
| Bach et al. | A case of necrolytic migratory erythema managed for 24 months with intravenous amino acid and lipid infusions | |
| FR2680687A1 (fr) | Compositions pharmaceutiques homeopathiques utilisees pour la fabrication de medicaments destines au traitement des maladies causees par des erreurs metaboliques et au traitement des maladies virales. | |
| Flanagan et al. | Antidotes: principles and clinical applications | |
| Harbord | Common toxidromes and the role of extracorporeal detoxification | |
| Gibbons et al. | Acute nonlymphocytic leukemia following short‐term, intermittent, intravenous cyclophosphamide treatment of lupus nephritis | |
| Gwaltney-Brant et al. | Newer antidotal therapies | |
| Merle et al. | Intractable epidermolysis bullosa acquisita: efficacy of Ciclosporin A | |
| Stark et al. | Dissolution of Cystine Calculi by Pelviocaliceal Irrigation with B-Penicillamine | |
| McKendry et al. | Clinical experience with DBI (phenformin) in the management of diabetes | |
| EP0655928B1 (fr) | Utilisation d'un produit homéopathique pour la préparation d'un médicament destiné au traitement de maladies métaboliques | |
| Menne et al. | Treatment of nickel dermatitis.(The influence of tetraethylthiuramdisulfide (Antabuse) on nickel metabolism) | |
| Rainsford et al. | Recent pharmacodynamic and pharmacokinetic findings on oxaprozin | |
| Burke | Gastric lavage and emesis in the treatment of ingested poisons: A review and a clinical study of lavage in ten adults | |
| Bleiberg et al. | Studies on derivatives of 2, 2-bis-(p-chlorophenyl)-1, 1-dichloroethane (DDD, TDE) with special reference to their effects on the adrenal cortex | |
| Oettmeier et al. | The procainebase-infusion: 20 years of experience of an alternative use with several therapeutical effects | |
| Tiscornia et al. | Analysis of the mechanism of action of calcium-induced exocrine pancreatic secretory changes in the dog. | |
| Albretsen | Oral medications | |
| EP1437140A1 (en) | Oral pharmaceutical formulation containing active carbon and use of the same |